Next Article in Journal
Chronic Non-Malignant Pain in Patients with Cancer Seen at a Timely Outpatient Palliative Care Clinic
Previous Article in Journal
Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma
Previous Article in Special Issue
Multifunctional Silica-Based Nanoparticles with Controlled Release of Organotin Metallodrug for Targeted Theranosis of Breast Cancer
Open AccessReview

Nanodrug Delivery Systems for the Treatment of Ovarian Cancer

Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, 7 York Road, Parktown 2193, South Africa
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(1), 213; https://doi.org/10.3390/cancers12010213
Received: 4 November 2019 / Revised: 12 December 2019 / Accepted: 13 December 2019 / Published: 15 January 2020
(This article belongs to the Special Issue Cancer Nanomedicine)
Despite advances achieved in medicine, chemotherapeutics still has detrimental side effects with ovarian cancer (OC), accounting for numerous deaths among females. The provision of safe, early detection and active treatment of OC remains a challenge, in spite of improvements in new antineoplastic discovery. Nanosystems have shown remarkable progress with impact in diagnosis and chemotherapy of various cancers, due to their ideal size; improved drug encapsulation within its interior core; potential to minimize drug degradation; improve in vivo drug release kinetics; and prolong blood circulation times. However, nanodrug delivery systems have few limitations regarding its accuracy of tumour targeting and the ability to provide sustained drug release. Hence, a cogent and strategic approach has focused on nanosystem functionalization with antibody-based ligands to selectively enhance cellular uptake of antineoplastics. Antibody functionalized nanosystems are (advanced) synthetic candidates, with a broad range of efficiency in specific tumour targeting, whilst leaving normal cells unaffected. This article comprehensively reviews the present status of nanosystems, with particular emphasis on nanomicelles for molecular diagnosis and treatment of OC. In addition, biomarkers of nanosystems provide important prospects as chemotherapeutic strategies to upsurge the survival rate of patients with OC. View Full-Text
Keywords: nanosystems; drug delivery; nanomicelles; ovarian cancer; tumour targeting; chemotherapeutics nanosystems; drug delivery; nanomicelles; ovarian cancer; tumour targeting; chemotherapeutics
Show Figures

Graphical abstract

MDPI and ACS Style

Pantshwa, J.M.; Kondiah, P.P.D.; Choonara, Y.E.; Marimuthu, T.; Pillay, V. Nanodrug Delivery Systems for the Treatment of Ovarian Cancer. Cancers 2020, 12, 213.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop